—According to researchers in Germany, the presence of additional cytogenetic or molecular markers included in current risk stratification systems, rather than the presence or absence of a trisomy 8, ...
In June 2024, multiple state regulators took joint action against Plutus Financial, Inc (Abra) ordering Abra to cease and desist certain operations in the U.S. and reimburse customers of virtual ...
SLS009 significantly improved survival in r/r AML patients, with a median overall survival of 8.8 months, surpassing historical benchmarks. The therapy showed a 67% objective response rate in AML-MRC ...
The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations. According to the updated results presented at ...
Anti-money laundering (AML) and KYC service provider Strise has raised $10.8 million in Series A funding. Atomico led the funding round, which included existing investors. A valuation of the company ...
Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. The ...
A USB port, a separate power supply and quality you can trust — “all for $1,500” — is what Wheatstone promises of its new AML 8-channel console. According to a company press release, the AML includes ...
All right. Good evening, everyone. Thanks for coming as we look forward to discussing the compelling initial results for CLN-049 that were presented at ASH today and also look forward to the promise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results